Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
volociximab + gemcitabine
- Development stage
- Phase 2
- Lead developer
- PDL BioPharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Volociximab + gemcitabine is an investigational combination therapy consisting of **volociximab**, a chimeric monoclonal antibody targeting the α5β1 integrin involved in tumor angiogenesis, and **gemcitabine**, a nucleoside analog chemotherapeutic agent. Volociximab works by binding to and inhibiting α5β1 integrin, thereby blocking the establishment of new blood vessels (angiogenesis) necessary for tumor growth. Gemcitabine inhibits DNA synthesis in rapidly dividing cells. This combination has been evaluated in metastatic pancreatic cancer for its safety and efficacy in enhancing anti-tumor effects[2][3].
02
Targets
DNA polymerase familyRNR (Ribonucleotide reductase)ITGA5:ITGB1 (Integrin α5β1)
Beyond the preview
Go deeper on volociximab + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on volociximab + gemcitabine.